FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

Confirmatory trial on tazemetostat suggested a link with secondary hematologic malignancie ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...

Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...